itacitinib

Ligand id: 8364

Name: itacitinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 119.62
Molecular weight 553.2
XLogP 2.28
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
INCB039110 is being assessed in Phase 2 clinical trials as a potential treatment for indications such as rheumatoid arthritis (RA), post essential thrombocythemia myelofibrosis, chronic plaque psoriasis and non-small cell lung cancer (NSCLC). Phase 3 trials in chronic graft-versus-host disease are also underway. Click here to link to ClinicalTrials.gov's complete list of INCB039110 studies.
Mechanism Of Action and Pharmacodynamic Effects
A wide range of cytokines signal via the Janus kinase (JAK) protein tyrosine kinases and signal transducers and activators of transcription (STAT) pathways. Inhibition of the Janus kinases is a highly competitive pharmaceutical field, as these inhibitors show beneficial activity against inflammatory disorders, autoimmune disorders, cancer, and other diseases where cytokine activity is disrupted.